biote (NASDAQ:BTMD – Get Free Report) and Henry Schein (NASDAQ:HSIC – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.
Profitability
This table compares biote and Henry Schein’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| biote | 3.19% | -22.33% | 12.10% |
| Henry Schein | 2.96% | 15.97% | 5.56% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for biote and Henry Schein, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| biote | 1 | 1 | 1 | 1 | 2.50 |
| Henry Schein | 1 | 6 | 8 | 0 | 2.47 |
Institutional and Insider Ownership
21.7% of biote shares are owned by institutional investors. Comparatively, 96.6% of Henry Schein shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 0.9% of Henry Schein shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
biote has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Henry Schein has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
Earnings & Valuation
This table compares biote and Henry Schein”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| biote | $192.22 million | 0.29 | $27.05 million | $0.11 | 14.00 |
| Henry Schein | $13.18 billion | 0.75 | $398.00 million | $3.43 | 25.83 |
Henry Schein has higher revenue and earnings than biote. biote is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.
Summary
Henry Schein beats biote on 8 of the 15 factors compared between the two stocks.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
About Henry Schein
Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.
